新股暗盤 | 瑞科生物-B(2179.HK)暗盤段漲2%
格隆匯3月30日丨據富途證券,瑞科生物-B(2179.HK)暗盤段現報25.25港元,較發行價24.8港元漲1.8%,總市值121億港元。公司主要專注於HPV候選疫苗的研發,現已建立12款候選疫苗組合。此次上市全球發售3085.45萬股,其中香港發售308.55萬股,國際發售2776.9萬股,每手500股,一手中籤率9.3%,香港公開發售獲10.65倍認購,淨籌6.724億港元,當中約47.3%分配予集團HPV疫苗管線(包括集團的核心產品,即REC603)的研發、生產及商業化;17.7%將用於新冠肺炎候選疫苗ReCOV。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.